Compare Home Depot Inc (HD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs TG Therapeutics Inc — how do they compare? Home Depot Inc trades at $291.42 (market cap $294.79B), while TG Therapeutics Inc trades at $54.9 (market cap $8.16B). The key difference: Home Depot Inc is far larger — about 36.1× TG Therapeutics Inc's market cap, and Home Depot Inc pays a 3.15% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and TG Therapeutics Inc for 16 Days on average.
| HD | TGTX | |
|---|---|---|
Market Cap | $294.79B | $8.16B |
Volume | 8,693,917 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $59.06 |
52-Week Low | $281.15 | $26.94 |
Typical Hold Time | 139 Days | 16 Days |
Enterprise Value | $355.27B | $8.37B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $291.17, up 1.89% today, with a bullish technical signal but mixed moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.92 exceeding expectations. Revenue for 2025 reached $159.51 billion, though net income margin has trended down to 8.41%. Analyst consensus is bullish with a $379.93 price target, but rising mortgage rates and weak big-ticket demand pose headwinds.
The outlook remains cautiously optimistic given HD's robust profitability and Pro business growth, but margin pressure and housing market sensitivity are key risks. Institutional activity shows mixed positioning, with some firms increasing stakes while others trim holdings. The stock's valuation at a P/E of 20.68 appears reasonable if earnings momentum continues.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
